Key points from article :
Metformin has been proposed as an anti-aging drug, but TAME may help pave the way to important future trials of longevity therapeutics.
Fewer chances are that metformin will slow the rate of aging in humans.
The animal (mice and rats) studies got many scientists excited about metformin in the first place but they went wrong.
Hevolution Foundation has agreed to provide the last tranche of funding for the long-delayed Targeting Aging with Metformin (TAME) trial.
TAME is a large-scale human trial to see if the cheap, safe diabetes drug metformin can slow aging in a cohort of several thousand aging but nondiabetic people.
Metformin very slightly increased median survival at a lower dose, but shortened life at the higher dose in mice.
Metformin failed to extend lifespan in the NIA’s Interventions Testing Program (ITP).
The results were published in the Aging cell.
